Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Artelo Biosciences, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −3 vs. Q2 2021
- Shares held
- 1.99M
- −784.8K (−28.3%) vs. Q2 2021
- Total value
- $1.57M
- −$1.72M (−52.3%) vs. Q2 2021
- New holders
- 0
- 8 more added
- Sold out
- 3
- 6 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.3K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $984.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 150 | $0 | 0.00% | +16+11.9% | Added |
| FMR LLC | 65 | $0 | 0.00% | −3−4.4% | Reduced |
| Advisor Group Holdings, Inc. | 35 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,014 | $1.00K | 0.00% | +1,005+11,166.7% | Added |
| Tower Research Capital LLC (TRC) | 9,902 | $8.00K | 0.00% | +6,598+199.7% | Added |
| LVM Capital Management Ltd | 12,000 | $9.00K | 0.00% | −8,000−40.0% | Reduced |
| Citadel Advisors LLC | 27,884 | $22.0K | 0.00% | −46,286−62.4% | Reduced |
| Two Sigma Advisers, LP | 35,600 | $28.0K | 0.00% | −224,400−86.3% | Reduced |
| Virtu Financial LLC | 43,012 | $34.0K | 0.00% | +20,418+90.4% | Added |
| Northern Trust Corp | 62,521 | $49.0K | 0.00% | +50,005+399.5% | Added |
| HighTower Advisors, LLC | 72,000 | $57.0K | 0.00% | +10,000+16.1% | Added |
| Bank of New York Mellon Corp | 86,603 | $68.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 122,895 | $97.0K | 0.00% | −119,088−49.2% | Reduced |
| Geode Capital Management, LLC | 162,750 | $128.0K | 0.00% | +22,139+15.7% | Added |
| Kepos Capital LP | 200,000 | $158.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 282,608 | $223.0K | 0.00% | −274,130−49.2% | Reduced |
| Vanguard Group Inc | 867,896 | $687.0K | 0.00% | +5,724+0.7% | Added |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −163,891−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −36,431−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −28,427−100.0% | Sold out |